During the past decade, Sarah Cannon Research Institute at Tennessee Oncology conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 9 clinical trials were completed, i.e. on average, 15.8% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 8 clinical trials were completed. i.e. 22.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon Research Institute at Tennessee Oncology" #1 sponsor was "Erasca, Inc." with 5 trials, followed by "Incyte Corporation" with 5 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Revolution Medicines, Inc." with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Research Institute at Tennessee Oncology" #1 collaborator was "Merck Sharp & Dohme LLC" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "Sanofi" with 2 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon Research Institute at Tennessee Oncology" are "Breast Cancer" (6 trials), "Lung Cancer" (5 trials), "Multiple Myeloma" (5 trials), "Solid Tumor" (5 trials) and "Ovarian Cancer" (4 trials). Many other conditions were trialed in "Sarah Cannon Research Institute at Tennessee Oncology" in a lesser frequency.

Most popular intervention types in "Sarah Cannon Research Institute at Tennessee Oncology" are "Drug" (58 trials), "Biological" (4 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (6 trials), "Placebo" (4 trials), "ERAS-007" (3 trials), "ERAS-601" (3 trials) and "Epacadostat" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon Research Institute at Tennessee Oncology" are 56 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Sarah Cannon Research Institute at Tennessee Oncology". undefined are not yet recruiting, 24 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Sarah Cannon Research Institute at Tennessee Oncology, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon Research Institute at Tennessee Oncology, 39 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".